Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors to treat important diseases, such as non-alcoholic steatohepatitis, acne, and various cancers. It offers Denifanstat, a fatty acid synthase inhibitor for the treatment of nonalcoholic steatohepatitis. The company also develops TVB-3567, a FASN inhibitor. Sagimet Biosciences Inc. was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. The company was incorporated in 2006 and is based in San Mateo, California.